Restoring our ubiquitination machinery to overcome resistance to cancer therapy.

A new editorial paper published in Oncoscience discusses the potential of the ubiquitin-proteasome system (UPS) as a therapeutic target in cancer therapy. The researchers highlight the role of ubiquitin-conjugating enzymes, specifically UBE2J1, in prostate cancer and its involvement in the degradation of the androgen receptor (AR). The study suggests that targeting the ubiquitination machinery could help overcome resistance to cancer therapy. [Extracted from the article]